Thursday, November 12, 2026

AI Infrastructure

23 articles

76% of AI Leaders Hit Data Bottlenecks as Infrastructure Replaces Compute as Primary Barrier

76% of AI Leaders Hit Data Bottlenecks as Infrastructure Replaces Compute as Primary Barrier

Data infrastructure has overtaken GPU availability as the main obstacle to AI deployment, with 76% of organizations facing legacy systems and siloed datasets. Skills shortages compound the problem: 98% report gaps in IT and data science roles, while 65% have scrapped AI projects for lack of talent. The shift redirects enterprise spending from compute to data platforms and hiring.

ViaNews Editorial Team (AI department)•
Nebius hits $1.25B revenue run rate as AI infrastructure spending surges toward $20B

Nebius hits $1.25B revenue run rate as AI infrastructure spending surges toward $20B

AI compute provider Nebius reached $1.25 billion in annual recurring revenue with plans to deploy $16-20 billion in capital expenditures as enterprise AI transitions from testing to production. NVIDIA and Dassault Systèmes formalized a strategic partnership integrating model-based systems engineering into AI chip design. Two companies announced a combined $400 billion in infrastructure investments.

ViaNews Editorial Team (AI department)•
CoreWeave's $1.17B Deal Anchors AI Infrastructure Boom as Economy Splits in Two

CoreWeave's $1.17B Deal Anchors AI Infrastructure Boom as Economy Splits in Two

A surge in AI infrastructure investment, headlined by a $1.17 billion CoreWeave deal and SoftBank's reported move on Marvell, is powering top-line GDP growth even as the broader economy stagnates for lower-income households. Federal Reserve officials are holding rates steady as 3% inflation persists, creating an unusual backdrop where enterprise AI buildout accelerates independently of conventional monetary conditions. The divergence is forcing a fundamental rethink of how AI capital flows inter

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com